PD-1抑制剂联合抗血管生成药物及化疗二线治疗晚期肺腺癌的临床对比分析

doi:10.11904/j.issn.1002-3070.2022.04.009

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (4): 339-345.doi: 10.11904/j.issn.1002-3070.2022.04.009

PD-1抑制剂联合抗血管生成药物及化疗二线治疗晚期肺腺癌的临床对比分析

连晓敏, 马峰, 赵丽霞, 孟玮, 赵丹丹, 赵峻峰

河北北方学院附属第一医院肿瘤内科(张家口 075000)

收稿日期:2021-12-06 修回日期:2022-05-30 出版日期:2022-08-28 发布日期:2022-08-29
通讯作者: 赵峻峰,E-mail:Zhaojunfengmin@163.com
作者简介:连晓敏,女,(1995-),硕士研究生,从事恶性肿瘤放化疗、靶向治疗及免疫治疗方向的研究。

Clinical comparative analysis of PD-1 inhibitor combined with anti-angiogenic drugs and chemotherapy in the second-line treatment of advanced lung adenocarcinoma

LIAN Xiaomin, MA Feng, ZHAO Lixia, MENG Wei, ZHAO Dandan, ZHAO Junfeng

Department of Medical Oncology,The First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,China

Received:2021-12-06 Revised:2022-05-30 Online:2022-08-28 Published:2022-08-29

摘要/Abstract

摘要： 目的本研究拟探讨程序性死亡受体1(Programmed cell death 1,PD-1)抑制剂联合抗血管生成药物及化疗二线治疗晚期肺腺癌的临床对比分析。方法回顾性分析河北北方学院附属第一医院2017年1月1日—2020年12月31日期间收治的99例晚期肺腺癌患者临床资料,根据不同治疗方法将患者分为单纯化疗组(n=35)、化疗联合抗血管生成药物组(n=34)和化疗联合抗血管生成药物联合免疫治疗组(n=30)。比较三组患者治疗后的临床疗效及不良反应发生情况。结果三组的疾病控制率(Disease control rate,DCR)分别为48.6%、55.9%和80.0%,差异有统计学意义(P=0.028);客观缓解率(Objective response rate,ORR)分别为11.4%、8.8%和23.3%,差异无统计学意义(P=0.273)。三组中位无进展生存期(Progression-free survival,PFS)分别为2.4个月、4.3个月和6.2个月,差异有统计学意义(P＜0.001)。治疗期间三组最常见的不良反应有白细胞减少、恶心呕吐、转氨酶升高、乏力等,大多为1~2级。单因素分析显示临床分期是影响PFS的独立因素。在考虑分组因素情况下,多因素Cox回归分析显示脑转移是PFS的独立影响因素。结论三组对比分析显示二线应用PD-1抑制剂联合抗血管生成药物及化疗治疗晚期肺腺癌的疗效确切且安全性良好。

关键词: 肺腺癌, 抗血管生成, PD-1抑制剂, 近期疗效, 安全性

Abstract: Objective The aim of this study was to investigate the clinical comparative analysis of anti-angiogenic drugs combined with programmed cell death 1(PD-1)inhibitor and chemotherapy in the second-line treatment of advanced lung adenocarcinoma.Methods A retrospective analysis of 99 patients with advanced lung adenocarcinoma admitted to The First Affiliated Hospital of Hebei North University from January 1,2017 to December 31,2020 was performed.They were divided into the simple chemotherapy group(n=35),chemotherapy combining with anti-angiogenic drugs group(n=34),and chemotherapy combined with anti-angiogenic drugs and immunotherapy group(n=30).The clinical efficacy and adverse reactions of the three groups were compared.Results The disease control rate(DCR)of the three groups were 48.6%,55.9% and 80.0%,respectively,and the difference was statistically significant(P=0.028).The Objective response rate(ORR)was 11.4%,8.8% and 23.3%,respectively,and the difference was not statistically significant(P=0.273).The median progression-free survival(PFS)of the three groups were 2.4 months,4.3 months and 6.2 months,respectively,and the difference was statistically significant(P＜0.001).During the treatment,the most common adverse reactions in the three groups were leukopenia,nausea and vomiting,elevated transaminases and fatigue,etc.and most of them were grade 1-2.Univariate analysis showed that clinical stage was an independent factor affecting PFS.Multivariate Cox regression analysis showed that brain metastasis was an independent prognostic factor of PFS after considering grouping factors.Conclusion The comparative analysis of the three groups showed that the second-line application of PD-1 inhibitor combined with anti-angiogenic drugs and chemotherapy in the treatment of advanced lung adenocarcinoma was effective and safe.

Key words: Lung adenocarcinoma, Anti-angiogenesis therapy, Programmed cell death 1 inhibitor, Short-term efficacy, Safety

中图分类号:

R734.2

连晓敏, 马峰, 赵丽霞, 孟玮, 赵丹丹, 赵峻峰. PD-1抑制剂联合抗血管生成药物及化疗二线治疗晚期肺腺癌的临床对比分析[J]. 实用肿瘤学杂志, 2022, 36(4): 339-345.

LIAN Xiaomin, MA Feng, ZHAO Lixia, MENG Wei, ZHAO Dandan, ZHAO Junfeng. Clinical comparative analysis of PD-1 inhibitor combined with anti-angiogenic drugs and chemotherapy in the second-line treatment of advanced lung adenocarcinoma[J]. Journal of Practical Oncology, 2022, 36(4): 339-345.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.04.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I4/339

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:Globocan estimates of incidence and mortality world wide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Gettinger SN,Horn L,Gandhi L,et al.Overall survival and long-term safety of nivolumab(Anti-Programmed Death 1 Antibody,BMS-936558,ONO-4538)in patients with previously treated advanced non-small-cell lung cancer[J].Clin Oncol,2015,33(18):2004-2012.
3 Wu YL,Lu S,Cheng Y,et al.Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC:CheckMate 078 randomized phase III clinical trial[J].Thorac Oncol,2019,14(5):867-875.
4 Herbst RS,Baas P,Kim DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer(KEYNOTE-010):a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.
5 Wu FTH,Xu P,Chow A,et al.Pre-and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro-or macro-metastatic disease[J].Br J Cancer,2019,120(2):196-206.
6 Liang H,Wang M.Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer[J].Cancer Manag Res,2019,11:7707-7719.
7 Huang Y,Kim BYS,Chan CK,et al.Improving immune-vascular crosstalk for cancer immunotherapy[J].Nat Rev Immunol,2018,18(3):195-203.
8 Reck M,Mok TSK,Nishio M,et al.Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer(IMpower150):key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised,open-label phase 3 trial[J].Lancet Respir Med,2019,7(5):387-401.
9 Manegold C,Dingemans AC,Gray JE,et al.The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC[J].Thorac Oncol,2017,12:194-207.
10 Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J].Clin Oncol,2004,22(9):1589-1597.
11 Cortot AB,Audigier-Valette C,Molinier O,et al.Weekly paclitaxel plus bevacizumab versus docetaxel as second-or third-line treatment in advanced non-squamous non-small-cell lung cancer:results of the IFCT-1103 ULTIMATE study[J].Eur J Cancer,2020,131:27-36.
12 Zhou C,Wang Y,Zhao J,et al.Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy[J].Clin Cancer Res,2021,27(5):1296-1304.
13 Xiong Q,Qin B,Xin L,et al.Real-world efficacy and safety of anlotinib with and without immunotherapy in advanced non-small cell lung cancer[J].Front Oncol,2021,11:659380.
14 Jiang S,Liang H,Liu Z,et al.The Impact of anlotinib on brain metastases of non-small cell lung cancer:post hoc analysis of a phase III randomized control trial(ALTER0303)[J].Oncologist,2020,25(5):870-874.
15 Dong ZY,Zhang JT,Liu SY,et al.EGFR mutation correlates with uninflamed phenotype and weak immunogenicity,causing impaired response to PD-1 blockade in non-small cell lung cancer[J].Oncoimmunology,2017,6(11):e1356145.
16 Liu SY,Dong ZY,Wu SP,et al.Clinical relevance of PD-L1 expression and CD8⁺T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer[J].Lung Cancer,2018,125:86-92.
17 Mok TSK,Wu YL,Kudaba I,et al.Pembrolizumab versus chemotherapy for previously untreated,pd-l1-expressing,locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042):a randomised,open-label,controlled,phase3trial[J].Lancet,2019(10183):1819-1830.
18 Li H,Xu Y,Wan B,et al.The clinicopathological and prognostic significance of pd-l1 expression assessed by immunohistochemistry in lung cancer:a meta-analysis of 50 studies with 11,383 patients[J].Transl Lung Cancer Res,2019,8(4):429-449.

[1]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[2]	刘佳, 杨道坤, 王燕平, 陈宝鑫, 王新伟, 申娇. PD-1抑制剂治疗肝细胞癌疗效相关生物标志物的研究现状[J]. 实用肿瘤学杂志, 2022, 36(4): 374-380.
[3]	卜建龙, 张品一, 倪博雄, 于夕冉, 宁金峰. 早期肺腺癌淋巴结转移的危险因素分析[J]. 实用肿瘤学杂志, 2022, 36(1): 26-30.
[4]	任凤海, 朱开彬, 王彦博, 周福成, 庞赛楠, 陈澜涛. NFATc1对人肺腺癌细胞增殖、凋亡和侵袭能力的影响[J]. 实用肿瘤学杂志, 2021, 35(5): 402-407.
[5]	王俊美, 潘慧卿, 李婧铱, 贾迪, 赵炜明, 吕昌莲. MT2-MMP在Ⅱ期肺腺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2021, 35(3): 243-247.
[6]	鲍瑜,朱立建(综述),钱江(审校). 抗血管生成药物治疗肺癌脑转移的研究新进展[J]. 实用肿瘤学杂志, 2021, 35(1): 91-96.
[7]	梁永琴, 赵宏伟. 抗血管生成药物在铂耐药卵巢癌中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 60-63.
[8]	李磊 , 张清媛. 乳腺癌抗肿瘤血管治疗的临床进展[J]. 实用肿瘤学杂志, 2019, 33(5): 461-465.
[9]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[10]	卞秀森, 李光, 关欣宇, 张伊, 狄畅, 马璨. UHRF1通过调控细胞自噬抑制肺腺癌细胞增殖的分子机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 498-502.
[11]	梁语丝, 谭永刚, 邹华伟审校. 低剂量化疗作用机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 538-542.
[12]	代欣综述, 张大昕审校. 非小细胞肺癌抗血管生成治疗研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 472-476.
[13]	骆莉萍,吴振启. 羟基喜树碱联合5-氟尿嘧啶于膀胱癌化疗中的疗效及安全性研究[J]. 实用肿瘤学杂志, 2016, 30(4): 300-303.
[14]	李富荣,程先硕,李云峰. 靶向血管生成拟态治疗肿瘤的研究进展[J]. 实用肿瘤学杂志, 2015, 29(4): 359-363.
[15]	李志伟王凤云张倩倩李丁楠张纯慧燕飞虎张艳桥. STAT3通过上调Twist基因表达从而诱导肺腺癌细胞上皮-间质转化[J]. 实用肿瘤学杂志, 2014, 28(4): 310-314.

PD-1抑制剂联合抗血管生成药物及化疗二线治疗晚期肺腺癌的临床对比分析

Clinical comparative analysis of PD-1 inhibitor combined with anti-angiogenic drugs and chemotherapy in the second-line treatment of advanced lung adenocarcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价